Premium
Low‐dose etretinate in the maintenance of remission of palmoplantar pustular psoriasis
Author(s) -
WHITE S.I.,
PUTTICK LINDA,
MARKS JANET M.
Publication year - 1986
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.1986.tb05768.x
Subject(s) - etretinate , medicine , dermatology , psoriasis , generalized pustular psoriasis , pustular psoriasis , maintenance therapy , complete remission , acitretin , chemotherapy
SUMMARY Twenty patients with palmoplantar pustular psoriasis were treated initially for 4 weeks with 70 mg etretinate daily. This led to clinical improvement and a significant fall in pustule count. The patients were then allocated randomly to 30 mg etretinate daily or placebo for a further 12 weeks. There was a rapid deterioration in the clinical condition and a rise in pustule count in the placebo group. The etretinate‐treated group still showed clinical improvement and a significantly lower pustule count after 12 weeks. Clinical side‐effects were few and adverse effects on liver function and serum lipids were not found.